Crossmark

Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial

Crossref DOI link: https://doi.org/10.1038/s41409-022-01777-5

Published Online: 2022-08-18

Published Print: 2022-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Finke, Jürgen https://orcid.org/0000-0002-1799-5927
Schmoor, Claudia

Stelljes, Matthias https://orcid.org/0000-0002-9331-5145
Burchert, Andreas https://orcid.org/0000-0002-8411-8844
Dreger, Peter https://orcid.org/0000-0002-7429-8570
Hegenbart, Ute https://orcid.org/0000-0003-1917-6746
Wagner-Drouet, Eva-Maria

Bornhäuser, Martin

Sohlbach, Kristina

Schub, Natalie

Reicherts, Christian

Kobbe, Guido

Glass, Bertram

Bertz, Hartmut

Grishina, Olga
Funding

Funding for this research was provided by:

Medac, Neovii, Riemser
License Information

Text and Data Mining valid from 2022-08-18

Version of Record valid from 2022-08-18
More Information

Article History

Received: 29 April 2022

Revised: 29 July 2022

Accepted: 3 August 2022

First Online: 18 August 2022

Competing interests

: JF had received travel, consultancy, and lecture fees from Medac, Neovii Biotech, Riemser, and HB travel fees from Neovii Biotech. CS and OG received an institutional research grant from Medac, Neovii Biotech, and Riemser for statistical planning and analysis.

Document is current

Any future updates will be listed below